Retatrutide vs Matrixyl
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Matrixyl
Matrixyl (Palmitoyl Pentapeptide-4) is a signal peptide that stimulates collagen and extracellular matrix production. It is one of the most well-studied anti-aging peptides with proven efficacy for wrinkle reduction.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | Matrixyl |
|---|---|---|
| Mechanism | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. | Mimics collagen breakdown fragments, triggering fibroblasts to produce new collagen, elastin, and other matrix components. Essentially tricks skin into repair mode without actual damage. |
| Typical Dosage | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. | Topical: 2-8% concentration in serums and creams. Matrixyl 3000 combines it with Palmitoyl Tetrapeptide-7 for enhanced effects. |
| Administration | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. | Topical application 1-2 times daily. Can be combined with other actives like retinol, vitamin C, and other peptides. |
| Side Effects | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. | Very well-tolerated. Rare mild irritation. Suitable for sensitive skin types. |
| Best For |